Search results
Showing 8071 to 8085 of 9079 results
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
Discontinued Reference number: GID-TA10447
Discontinued Reference number: GID-TA10452
Atezolizumab for untreated advanced renal cell carcinoma [ID1365]
Discontinued Reference number: GID-TA10338
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
Discontinued Reference number: GID-TA10341
Discontinued Reference number: GID-TA10353
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
Discontinued Reference number: GID-TA10242
Discontinued Reference number: GID-TA10264
Discontinued Reference number: GID-TA10297
Discontinued Reference number: GID-TA10308
Bevacizumab for untreated malignant pleural mesothelioma [ID1183]
Discontinued Reference number: GID-TA10197
Selumetinib for treating differentiated thyroid cancer [ID1079]
Discontinued Reference number: GID-TA10207
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]
Discontinued Reference number: GID-TA10213
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued Reference number: GID-TA10177